Differences between patients with nraxSpA and AS stratified according to BASDAI level.
| Characteristics | BASDAI | nraxSpA | AS | p Value AS versus nraxSpA | p Value BASDAI total group <4 vs ≥4 |
|---|---|---|---|---|---|
| NRS pain | <4 | 2.3±1.2 | 2.3±1.7 | 0.7 | <0.001 |
| ≥4 | 5.5±1.7 | 6.3±2.3 | 0.2 | ||
| CRP (mg/l) | <4 | 6.0±6.5 | 11.7±11.7 | 0.04 | 0.8 |
| ≥4 | 5.4±6.8 | 11.6±13.6 | 0.005 | ||
| ASDAS | <4 | 1.7±0.6 | 2.0±0.7 | 0.2 | <0.001 |
| ≥4 | 2.7±0.8 | 3.5±0.6 | 0.002 | ||
| Physician's global | <4 | 2.6±1.9 | 2.8±2.1 | 1.0 | 0.03 |
| ≥4 | 2.7±1.7 | 4.1±1.8 | 0.02 | ||
| Patient's global | <4 | 2.1±2.1 | 2.4±1.6 | 0.3 | <0.001 |
| ≥4 | 5.7±2.2 | 6.2±2.2 | 0.4 | ||
| BASFI | <4 | 0.8±0.7 | 1.2±1.1 | 0.4 | <0.001 |
| ≥4 | 3.3±2.2 | 4.8±2.1 | 0.02 | ||
| ASQoL | <4 | 2.3±3.1 | 2.0±2.4 | 0.9 | <0.001 |
| ≥4 | 8.4±4.1 | 9.0±4.2 | 0.6 | ||
| SF-36 PCS | <4 | 44.7±6.6 | 43.8±9.1 | 0.9 | 0.009 |
| ≥4 | 34.2±8.6 | 30.3±7.0 | 0.07 | ||
| SF-36 MCS | <4 | 48.1±11.1 | 50.4±12.7 | 0.4 | <0.001 |
| ≥4 | 41.8±13.7 | 44.5±10.6 | 0.6 | ||
| Inflammatory lesions/patient (n) | <4 | 0.9±1.4 | 3.6±3.7 | 0.009 | 0.6 |
| ≥4 | 0.5±0.6 | 2.7±3.0 | 0.008 | ||
| Characteristics | ASDAS | nraxSpA | AS | p Value AS versus nraxSpA | p Value ASDAS total group <2.1 versus ≥2.1 |
| NRS pain | <2.1 | 2.8±1.6 | 1.5±1.0 | 0.02 | <0.001 |
| ≥2.1 | 5.0±1.8 | 5.5±2.3 | 0.3 | ||
| CRP (mg/l) | <2.1 | 2.2±2.2 | 5.1±4.4 | 0.04 | 0.006 |
| ≥2.1 | 8.6±7.5 | 13.4 ±13.6 | 0.07 | ||
| BASDAI | <2.1 | 2.6±1.1 | 1.5±0.8 | 0.009 | 0.001 |
| ≥2.1 | 4.4±1.5 | 4.9±1.8 | 0.3 | ||
| Physician's global | <2.1 | 2.6±2.0 | 2.0±1.5 | 0.5 | 0.1 |
| ≥2.1 | 2.8±1.5 | 3.8±1.8 | 0.03 | ||
| Patient's global | <2.1 | 2.4±2.2 | 1.6±2.2 | 0.5 | <0.001 |
| ≥2.1 | 5.2±2.3 | 5.4±2.4 | 0.8 | ||
| BASFI | <2.1 | 1.2±1.4 | 0.7±0.8 | 0.4 | <0.001 |
| ≥2.1 | 3.2±2.1 | 3.9±2.2 | 0.2 | ||
| ASQoL | <2.1 | 3.7±3.9 | 2.0±0.5 | 0.1 | 0.018 |
| ≥2.1 | 7.2±4.8 | 7.1±4.6 | 0.9 | ||
| SF-36 PCS | <2.1 | 43.8±7.3 | 47.1±8.0 | 0.2 | <0.001 |
| ≥2.1 | 43.4±8.1 | 33.2±8.5 | 0.5 | ||
| SF-36 MCS | <2.1 | 49.1±9.6 | 50.2±11.9 | 0.5 | 0.18 |
| ≥2.1 | 41.2±13.3 | 46.6±11.4 | 0.1 | ||
| Inflammatory lesions/patient (n) | <2.1 | 0.65±0.8 | 3.83±4.1 | 0.005 | 0.58 |
ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath AS Functional Index; CRP, C-reactive protein; nraxSpA, non-radiographic axial spondyloarthritis; MCS, mental component summary score; NRS, numerical rating scale; PCS, physical component summary score; SF-36, Short Form-36 Health Survey.